Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.

Autor:	Stuart, Arabella S V1,2 (AUTHOR), Shaw, Robert H1,2 (AUTHOR), Liu, Xinxue1 (AUTHOR), Greenland, Melanie1 (AUTHOR), Aley, Parvinder K1 (AUTHOR), Andrews, Nick J3,4 (AUTHOR), Cameron, J C5 (AUTHOR), Charlton, Sue6 (AUTHOR), Clutterbuck, Elizabeth A1 (AUTHOR), Collins, Andrea M7 (AUTHOR), Darton, Tom8,9 (AUTHOR), Dinesh, Tanya1 (AUTHOR), Duncan, Christopher J A10,11 (AUTHOR), England, Anna6 (AUTHOR), Faust, Saul N12,13 (AUTHOR), Ferreira, Daniela M7 (AUTHOR), Finn, Adam14 (AUTHOR), Goodman, Anna L15,16 (AUTHOR), Green, Christopher A17,18 (AUTHOR), Hallis, Bassam6 (AUTHOR)
Zdroj:	Lancet. Jan2022, Vol. 399 Issue 10319, p36-49. 14p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu